WO2001087929A3 - Regulation de recepteur couple aux proteines g de type dopamine humain - Google Patents

Regulation de recepteur couple aux proteines g de type dopamine humain Download PDF

Info

Publication number
WO2001087929A3
WO2001087929A3 PCT/EP2001/005559 EP0105559W WO0187929A3 WO 2001087929 A3 WO2001087929 A3 WO 2001087929A3 EP 0105559 W EP0105559 W EP 0105559W WO 0187929 A3 WO0187929 A3 WO 0187929A3
Authority
WO
WIPO (PCT)
Prior art keywords
protein
coupled receptor
regulation
human dopamine
obesity
Prior art date
Application number
PCT/EP2001/005559
Other languages
English (en)
Other versions
WO2001087929A2 (fr
Inventor
Shyam Ramakrishnan
Original Assignee
Bayer Ag
Shyam Ramakrishnan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag, Shyam Ramakrishnan filed Critical Bayer Ag
Priority to DE60125169T priority Critical patent/DE60125169T2/de
Priority to AU67445/01A priority patent/AU6744501A/en
Priority to DK01945139T priority patent/DK1287133T3/da
Priority to EP01945139A priority patent/EP1287133B1/fr
Publication of WO2001087929A2 publication Critical patent/WO2001087929A2/fr
Publication of WO2001087929A3 publication Critical patent/WO2001087929A3/fr
Priority to CY20071100122T priority patent/CY1105966T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne des réactifs qui permettent la régulation du récepteur couplé aux protéines G, de type dopamine, humain, ainsi que des réactifs qui se lient aux produits géniques du récepteur couplé aux protéines G, de type dopamine, humain. Ces réactifs peuvent jouer un rôle dans la prévention, l'amélioration ou la correction de dysfonctionnements ou de maladies, tels que l'obésité et les maladies apparentées à l'obésité, le cancer, les diabètes, l'ostéoporose, l'anxiété, la dépression, l'hypertension, la migraine, les troubles compulsifs, la schizophrénie, l'autisme, les maladies neurodégénératives, telles que la maladie d'Alzheimer, la maladie de Parkinson et la chorée de Huntington, ainsi que les vomissements provoqués par une chimiothérapie anticancéreuse.
PCT/EP2001/005559 2000-05-18 2001-05-16 Regulation de recepteur couple aux proteines g de type dopamine humain WO2001087929A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
DE60125169T DE60125169T2 (de) 2000-05-18 2001-05-16 Regulation eines menschlichen dopamine-ähnlichen g-protein gekoppelten rezeptor.
AU67445/01A AU6744501A (en) 2000-05-18 2001-05-16 Regulation of human dopamine-like g protein-coupled receptor
DK01945139T DK1287133T3 (da) 2000-05-18 2001-05-16 Regulering af human dopamin-lignende G-protein-koblet receptor
EP01945139A EP1287133B1 (fr) 2000-05-18 2001-05-16 Regulation de recepteur couple aux proteines g de type dopamine humain
CY20071100122T CY1105966T1 (el) 2000-05-18 2007-01-29 Ρυθμιση ντοπαμινικων υποδοχεων ανθρωπου συζευγμενων με πρωτεϊνη g

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20519500P 2000-05-18 2000-05-18
US60/205,195 2000-05-18

Publications (2)

Publication Number Publication Date
WO2001087929A2 WO2001087929A2 (fr) 2001-11-22
WO2001087929A3 true WO2001087929A3 (fr) 2002-05-30

Family

ID=22761200

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/005559 WO2001087929A2 (fr) 2000-05-18 2001-05-16 Regulation de recepteur couple aux proteines g de type dopamine humain

Country Status (9)

Country Link
EP (1) EP1287133B1 (fr)
AT (1) ATE348162T1 (fr)
AU (1) AU6744501A (fr)
CY (1) CY1105966T1 (fr)
DE (1) DE60125169T2 (fr)
DK (1) DK1287133T3 (fr)
ES (1) ES2278755T3 (fr)
PT (1) PT1287133E (fr)
WO (1) WO2001087929A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8883714B2 (en) 2008-04-07 2014-11-11 Arena Pharmaceuticals, Inc. Pharmaceutical compositions comprising GPR119 agonists which act as peptide YY (PYY) secretagogues

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7816492B2 (en) 1998-11-20 2010-10-19 Arena Pharmaceuticals, Inc. Human G protein-coupled receptors
USRE42190E1 (en) 1998-11-20 2011-03-01 Arena Pharmaceuticals, Inc. Method of identifying a compound for inhibiting or stimulating human G protein-coupled receptors
US20030017528A1 (en) 1998-11-20 2003-01-23 Ruoping Chen Human orphan G protein-coupled receptors
ATE348152T1 (de) * 2000-12-01 2007-01-15 Astellas Pharma Inc Verfahren zum screening von diabetes- heilverfahren
GEP20084540B (en) 2003-01-14 2008-11-25 Arena Pharm Inc 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
US7083933B1 (en) 2003-05-09 2006-08-01 Prosidion Limited Methods for identification of modulators of OSGPR116 activity
AR045047A1 (es) 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
TWI335328B (en) 2003-07-14 2011-01-01 Arena Pharm Inc Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related hereto
DOP2006000008A (es) 2005-01-10 2006-08-31 Arena Pharm Inc Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
MY148521A (en) 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
DOP2006000010A (es) 2005-01-10 2006-07-31 Arena Pharm Inc Procedimiento para preparar eteres aromáticos
PE20071221A1 (es) * 2006-04-11 2007-12-14 Arena Pharm Inc Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
PL1971862T3 (pl) * 2006-04-11 2011-04-29 Arena Pharm Inc Sposoby stosowania receptora GPR119 w celu identyfikacji związków przydatnych w zwiększeniu masy kostnej osobnika
WO2009038974A1 (fr) 2007-09-20 2009-03-26 Irm Llc Composés et compositions en tant que modulateurs de l'activité de gpr119
CA2812061A1 (fr) 2010-09-22 2012-03-29 Arena Pharmaceuticals, Inc. Modulateurs du recepteur gpr119 et traitement des troubles qui lui sont lies
AU2016205361C1 (en) 2015-01-06 2021-04-08 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
KR102603199B1 (ko) 2015-06-22 2023-11-16 아레나 파마슈티칼스, 인크. Ｓ1ｐ1 수용체-관련 장애에서의 사용을 위한 (ｒ)-2-(7-(4-시클로펜틸-3-(트리플루오로메틸)벤질옥시)-1,2,3,4-테트라히드로시클로-펜타[ｂ]인돌-3-일)아세트산 (화합물 1)의 결정성 ｌ-아르기닌 염

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000022131A2 (fr) * 1998-10-13 2000-04-20 Arena Pharmaceuticals, Inc. Recepteurs non-endogenes de la proteine g humaine ayant une activite constitutive
WO2000031258A2 (fr) * 1998-11-20 2000-06-02 Arena Pharmaceuticals, Inc. Recepteurs humains couples a la proteine g orphan
WO2000050562A2 (fr) * 1999-02-22 2000-08-31 Synaptic Pharmaceutical Corporation Adn codant le recepteur snorf25
EP1092727A2 (fr) * 1999-09-30 2001-04-18 Pfizer Limited Recepteur de proteine g
WO2001032864A2 (fr) * 1999-11-03 2001-05-10 Merck Patent Gmbh Nouveaux polypeptides de type gpcr_kd5 et sequences d'adn correspondantes
WO2001036473A2 (fr) * 1999-11-16 2001-05-25 Pharmacia & Upjohn Company Recepteurs couples a une proteine g
WO2001042288A2 (fr) * 1999-12-10 2001-06-14 Incyte Genomics, Inc. Recepteurs couples a la proteine g

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000022131A2 (fr) * 1998-10-13 2000-04-20 Arena Pharmaceuticals, Inc. Recepteurs non-endogenes de la proteine g humaine ayant une activite constitutive
WO2000031258A2 (fr) * 1998-11-20 2000-06-02 Arena Pharmaceuticals, Inc. Recepteurs humains couples a la proteine g orphan
WO2000050562A2 (fr) * 1999-02-22 2000-08-31 Synaptic Pharmaceutical Corporation Adn codant le recepteur snorf25
EP1092727A2 (fr) * 1999-09-30 2001-04-18 Pfizer Limited Recepteur de proteine g
WO2001032864A2 (fr) * 1999-11-03 2001-05-10 Merck Patent Gmbh Nouveaux polypeptides de type gpcr_kd5 et sequences d'adn correspondantes
WO2001036473A2 (fr) * 1999-11-16 2001-05-25 Pharmacia & Upjohn Company Recepteurs couples a une proteine g
WO2001042288A2 (fr) * 1999-12-10 2001-06-14 Incyte Genomics, Inc. Recepteurs couples a la proteine g

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL 12 February 1999 (1999-02-12), A. PEARCE: "HUMAN DNA SEQUENCE FROM CLONE 20I3 ON CHROMOSOME XQ25-26 CONTAINS A GENE FOR BRAIN MITOCHONDRIAL CARRIER PROTEIN-1 (BMCP1), ESTS, STSS, GSSS AND A CPG ISLAND", XP002166396 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8883714B2 (en) 2008-04-07 2014-11-11 Arena Pharmaceuticals, Inc. Pharmaceutical compositions comprising GPR119 agonists which act as peptide YY (PYY) secretagogues

Also Published As

Publication number Publication date
ES2278755T3 (es) 2007-08-16
DE60125169T2 (de) 2007-11-22
DE60125169D1 (de) 2007-01-25
CY1105966T1 (el) 2011-04-06
EP1287133B1 (fr) 2006-12-13
PT1287133E (pt) 2007-03-30
ATE348162T1 (de) 2007-01-15
DK1287133T3 (da) 2007-03-26
EP1287133A2 (fr) 2003-03-05
AU6744501A (en) 2001-11-26
WO2001087929A2 (fr) 2001-11-22

Similar Documents

Publication Publication Date Title
WO2001087929A3 (fr) Regulation de recepteur couple aux proteines g de type dopamine humain
WO2002038760A3 (fr) Regulation du recepteur-detecteur de calcium extracellulaire couple a la proteine g humain
WO2001092297A3 (fr) Regulation du recepteur couple a la proteine g analogue du lgr-4 humain
WO2001088127A3 (fr) Régulation du récepteur couplé à la protéine g analogue à l'hormone folliculo-stimulante humaine
WO2001092296A3 (fr) Regulation du recepteur couple a une proteine g de type isotocine humaine
WO2002028898A3 (fr) Regulation du recepteur couple a la proteine g analogue au recepteur de la secretine humaine
WO2002029050A3 (fr) Regulation du gpcr du type recepteur de la secretine humaine
AU2002250949A1 (en) Human g protein-coupled receptor
WO2004080373A3 (fr) Agents diagnostiques et therapeutiques destines a des maladies associees au recepteur 2 active par la proteinase (par2) couple aux proteines g
WO2002000701A3 (fr) Regulation du recepteur humain couple a la proteine g semblable au recepteur de l'hormone liberant la gonadotropine
WO2002029052A3 (fr) Regulation du recepteur de secretine humaine de type gpcr
WO2002029051A3 (fr) Regulation de recepteurs couples a la proteine g (gpcr) de type recepteurs de secretine humaine
WO2002059302A3 (fr) Regulation du recepteur humain couple a la proteine g semblable a serotonine
WO2001077149A3 (fr) Regulation d'une proteine gpcr type cyslt2 humaine
WO2001070812A3 (fr) Regulation du recepteur couple aux proteines g de type h2 de l'histamine humaine
WO2001088126A3 (fr) Regulation du recepteur couple aux proteines g du type recepteur adrenergique $g(a)1a humain
WO2002042435A3 (fr) Regulation de la tyrosine phosphatase humaine
WO2002031160A3 (fr) Regulation de l'enzyme de type a2 phospholipase humaine
WO2002099107A3 (fr) Regulation du recepteur ta5 humain
WO2003072767A3 (fr) Regulation de la lipase humaine
WO2002032958A3 (fr) Regulation de l'immunorecepteur des cellules dendritiques humaines
WO2004048978A3 (fr) Procedes pour diagnostiquer et traiter des maladies associees au recepteur 37 couple a la proteine g d'acide biliaire (bg37)
WO2004029086A3 (fr) Regulation de l'homologue 3 du recepteur humain d'alpha-latrotoxine independant de calcium
WO2002031162A3 (fr) Regulation de l'enzyme du type phospholipase a2 humaine
WO2004099248A3 (fr) Produits de diagnostic et de traitement de maladies associees au recepteur agtr2 couple aux proteines g (agtr2)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2001945139

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10276547

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2001945139

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWG Wipo information: grant in national office

Ref document number: 2001945139

Country of ref document: EP